Detalhe da pesquisa
1.
Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.
Future Oncol
; 17(30): 4011-4025, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34337973
2.
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
Eur Radiol
; 30(9): 5021-5028, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32323012
3.
Combination treatments with immunotherapy in brain metastases patients.
Future Oncol
; 16(23): 1691-1705, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32412817
4.
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
BMC Med
; 15(1): 55, 2017 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28285592
5.
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
Curr Opin Oncol
; 29(2): 97-104, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28059852
6.
Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Clin Chem
; 63(3): 751-760, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28073897
7.
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Curr Opin Oncol
; 28(2): 122-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26756384
8.
AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
Future Oncol
; 11(22): 3069-81, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26450446
9.
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Future Oncol
; 11(8): 1245-57, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25629371
10.
First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
J Clin Oncol
; 42(4): 378-382, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38033277
11.
New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.
Am Soc Clin Oncol Educ Book
; 44(3): e432516, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38560815
12.
Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
J Thorac Oncol
; 19(2): 199-215, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37783386
13.
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.
Clin Transl Oncol
; 26(2): 352-362, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37490262
14.
Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC.
J Thorac Oncol
; 19(1): 119-129, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37572870
15.
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
J Thorac Oncol
; 19(1): 166-172, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37567387
16.
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
J Clin Oncol
; 42(12): 1350-1356, 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324744
17.
Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey.
JTO Clin Res Rep
; 4(1): 100446, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36687558
18.
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis.
Eur J Cancer
; 180: 117-124, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36592506
19.
MET alterations in NSCLC-Current Perspectives and Future Challenges.
J Thorac Oncol
; 18(4): 419-435, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36441095
20.
A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
Clin Transl Oncol
; 25(1): 283-291, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36168085